Navigation Links
Encorium Announces Receipt of Letter from Nasdaq Regarding its Third Quarter 2008 Form 10-Q Filing
Date:11/28/2008

WAYNE, Pa., Nov. 28 /PRNewswire-FirstCall/ -- Encorium Group, Inc. (Nasdaq: ENCO), a full service multinational clinical research organization (CRO) conducting studies in over 30 countries for many of the world's leading pharmaceutical and biotechnology companies, today announced that on November 21, 2008, it received a letter from Nasdaq stating that since it had not yet filed its 10-Q for the quarterly period ended September 30, 2008 as of the date of the letter, it was no longer in compliance with the rules for continued listing according to Marketplace Rule 4310(c)(14).

The Nasdaq letter advised that Encorium had 60 calendar days from the date of the letter to submit a plan to regain compliance. Encorium filed its Form 10-Q for the quarterly period ended September 30, 2008 on Wednesday, November 26, 2008 and has notified Nasdaq of its filing. As a result, the Company anticipates it will receive notice from Nasdaq that it is currently in compliance with Nasdaq Marketplace Rule 4310(c)(14).

About Encorium Group, Inc.

Encorium Group, Inc. is a global clinical research organization specializing in the design and management of complex clinical trials and Patient Registries for the pharmaceutical, biotechnology and medical device industries. The Company's mission is to provide its clients with high quality, full-service support for their biopharmaceutical and medical device development programs. Encorium offers therapeutic expertise, experienced team management and advanced technologies. The Company has drug and biologics development as well as clinical trial experience across a wide variety of therapeutic areas such as infectious diseases, cardiovascular, vaccines, oncology, diabetes endocrinology/metabolism, gene therapy, immunology, neurology, gastroenterology, dermatology, hepatology, women's health an
'/>"/>

SOURCE Encorium Group, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Encorium Appoints David Ginsberg President and Chief Executive Officer, Announces Changes to the Board of Directors
2. Encorium Reports Third Quarter 2008 Financial Results
3. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
4. YM BIOSCIENCES ANNOUNCES COMPLIANCE WITH AIM RULE 26
5. Emisphere Technologies, Inc. Announces Pricing of Registered Direct Offering
6. BioLife Solutions Announces Exclusive CryoStor(TM) Supply Agreement With the New England Cryogenic Center, Inc.
7. Carrington Announces Nasdaq Communication; Prepares for Shares to Be Quoted on the OTC Bulletin Board and Pink Sheets
8. China Kangtai Cactus Biotech Files 2nd Quarter 2007 10QSB and Announces Unaudited Quarterly Results
9. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
10. Advanced Life Sciences Announces Receipt of Nasdaq Staff Letter
11. ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/22/2015)...   Cypher Genomics, Inc., the leading genome ... SQNM ), the leading molecular diagnostics company, today ... prenatal tests (NIPT). Through this agreement, Sequenom will ... advance analysis of clinically-relevant fetal sub-chromosomal variants detected ...
(Date:12/24/2014)... Dec. 24, 2014  United Therapeutics Corporation (NASDAQ: ... MDT ) has submitted a pre-market approval application ... the use of Medtronic,s SynchroMed ® II implantable ... use with United Therapeutics, Remodulin ® (treprostinil) Injection ...
(Date:12/24/2014)... GMO corn cases filed across the United States, and ... being consolidated in a Kansas federal court for pretrial proceedings. ... Corn Litigation, MDL No. 2591 in the U.S. District Court ... GMO corn multidistrict litigation (MDL) has been handed over to ...
(Date:12/24/2014)... 23, 2014 The report provides ... definition, classification, application and industry overview. This report ... cost structure. Production is separated by regions, technology ... materials, equipment, downstream client survey, marketing channels, industry ...
Breaking Biology Technology:Cypher Genomics and Sequenom Announce Development Agreement 2Cypher Genomics and Sequenom Announce Development Agreement 3Cypher Genomics and Sequenom Announce Development Agreement 4United Therapeutics Announces Submission Of Pre-Market Approval Application For Implantable Drug Infusion System To Deliver Remodulin 2United Therapeutics Announces Submission Of Pre-Market Approval Application For Implantable Drug Infusion System To Deliver Remodulin 3United Therapeutics Announces Submission Of Pre-Market Approval Application For Implantable Drug Infusion System To Deliver Remodulin 4Carey Danis & Lowe Reports on Syngenta GMO Corn Transfer Order 2Worldwide Methyl Mercaptan Market 2015-2020 Forecasts on Development & Trends Now Available at ReportsnReports.com 2
... lead sponsorship of the International Genetically Engineered ... by the Massachusetts Institute of Technology (MIT). ... undergraduate teams representing more than 1,000 students ... America, and the U.S. to design and ...
... preliminary data,from a Phase II/III clinical trial of ... heart failure will be presented next,week at a ... Sessions 2008 in New Orleans., John R. ... Francisco, will present the data from the multicenter, ...
... Nov. 3 Verenium Corporation,(Nasdaq: VRNM ), ... and high-performance specialty enzymes, announced today that it,will ... November 10,2008 after market close. In conjunction with ... with live webcast on Monday, November 10 at ...
Cached Biology Technology: The MathWorks Sponsors iGEM Competition for Synthetic Biology at MIT : MATLAB and SimBiology Help Accelerate Design of Synthetic Biological Systems 2 The MathWorks Sponsors iGEM Competition for Synthetic Biology at MIT : MATLAB and SimBiology Help Accelerate Design of Synthetic Biological Systems 3Top-Line Preliminary Data From Phase II/III Study of Corthera's Relaxin in Acute Heart Failure to be Presented in Satellite Symposium at AHA Scientific Sessions 2008 2Verenium Corporation to Announce Third Quarter 2008 Financial Results 2Verenium Corporation to Announce Third Quarter 2008 Financial Results 3
(Date:12/24/2014)... , Dec. 23, 2014  Since its launch in December 2014, ... to eliminate the pain of trying to remember their usernames ... biometrics fused to their smartphones. To assist people who have ... the company that created 1U and focuses on redefining identity, ...
(Date:12/22/2014)... Dec. 22, 2014  The 2014 Holiday Season may be ... Market Intelligence reports that the long anticipated floodgates for ... intensifying demand for smart phones, tablets, and wearable mobile ... of 2.5 billion users with nearly 4.8 billion biometric ...
(Date:12/19/2014)... Dec. 18, 2014  23andMe, Inc., the leading personal genetics company, ... differences in genetic ancestry of individuals from across ... arrived more than four hundred years ago, the ... for peoples from different continents. This study illuminates how American ...
Breaking Biology News(10 mins):1U Offers Best Solution to the Username / Password Dilemma: For FREE! 21U Offers Best Solution to the Username / Password Dilemma: For FREE! 3First Season of Holiday Shopping with Mobile Biometric Payments Wraps Up With a Present for Biometrics Industry: A Rosy Forecast for More Than 2 Billion Users of 4.8 Billion Mobile Biometric Devices by 2020 223andMe Study Sketches Genetic Portrait of the United States 223andMe Study Sketches Genetic Portrait of the United States 323andMe Study Sketches Genetic Portrait of the United States 4
... Brown University, with lead partner Women & Infants ... five-year contract to expand its participation in the National ... child health. The National Institute of Child Health ... and Centers at the National Institutes of Health, announced ...
... discovery that counters prevailing thought, a study in mice ... involved in "fat-burning" can actually increase energy expenditure and ... week in the JBC, might lead to ... and other warm-blooded animals need to continually "burn fat" ...
... a keystone species, filling such an important niche in ... Scientists are finding, however, that sea otters can have ... alter the behavior of another top predator: the bald ... can reach heights of 250 feet and function much ...
Cached Biology News:Brown University and Women & Infants Hospital expand national children's study to Bristol County 2Brown University and Women & Infants Hospital expand national children's study to Bristol County 3Brown University and Women & Infants Hospital expand national children's study to Bristol County 4Making metabolism more inefficient can reduce obesity 2Decline in Alaskan sea otters affects bald eagles' diet 2Decline in Alaskan sea otters affects bald eagles' diet 3
... Magnetofection technology, SilenceMag is the most ... rapid and easy to use, SilenceMag ... Specifically designed for siRNA delivery, SilenceMag ... low doses of siRNA.,SilenceMag formulation gives ...
... DW4 liquid handling system from Molecular Devices ... in one instrument. The system handles a ... plate washing96-, 384- and 1536-welland is the ... DW4 has been optimized to dispense from ...
... Radiochemical Purity is >95%NEN Radiolabeled Ligands\n\nReceptor-related ... continual availability of new radiolabeled ligands selected ... offers a wide range of products and ... including over 400 state-of-the-art radioligands. If you ...
... Radiolabeled Ligands\n\nReceptor-related research has long been enabled ... ligands selected to keep pace with new ... products and services for receptor research and ... If you do not find exactly what ...
Biology Products: